Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Cancer Vaccines01:30

Cancer Vaccines

321
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
321
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis.

JCO precision oncology·2026
Same author

Age-related differences in outcomes and tumor characteristics of ultra-rare sarcomas: A Nation-wide Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Nature communications·2026
Same author

Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Aristolochic Acid and Alternative Lengthening of Telomeres Mechanisms Underlie Liver Angiosarcoma Pathogenesis.

Liver cancer·2025
Same author

Prognostic significance of positive surgical margins for scalp angiosarcoma.

Journal of the Formosan Medical Association = Taiwan yi zhi·2025

Related Experiment Video

Updated: May 23, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K

Angiosarcoma: Role of Immunotherapy.

Tom Wei-Wu Chen1,2,3

  • 1Department of Oncology and Center of Excellence for Sarcoma, National Taiwan University Hospital, 7 Chung Shan South Rd, Taipei, Taiwan, 100. tomweiwuchen@ntu.edu.tw.

Current Treatment Options in Oncology
|March 8, 2025
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) show varied results in angiosarcoma treatment. Combinations with tyrosine kinase inhibitors (TKIs) show promise, while chemotherapy-ICI strategies require further research for optimal patient selection.

Keywords:
AngiosarcomaAntiangiogenic agentChemotherapyImmune checkpoint inhibitorImmunotherapyTumor genomics

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

Related Experiment Videos

Last Updated: May 23, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Treatment Research

Background:

  • Angiosarcoma treatment has seen varied outcomes with immune checkpoint inhibitors (ICIs).
  • Subtypes of angiosarcoma respond differently to single-agent ICI therapy, with UV- and radiation-associated types showing higher response rates possibly due to increased tumor mutation burden (TMB).
  • Dual ICI therapy shows potential but is limited in cutaneous angiosarcoma.

Purpose of the Study:

  • To review recent clinical trial results of ICIs alone, with tyrosine kinase inhibitors (TKIs), or with chemotherapy in angiosarcoma.
  • To evaluate the efficacy and limitations of different ICI-based treatment strategies across angiosarcoma subtypes.
  • To identify promising therapeutic combinations and areas for future research, including biomarker development.

Main Methods:

  • Review of recent clinical trials investigating ICI monotherapy, ICI-TKI combinations, and ICI-chemotherapy combinations in angiosarcoma.
  • Analysis of objective response rates (ORR) and progression-free survival (PFS) data from key trials like SWOG S1609 and Alliance A091902.
  • Examination of subgroup analyses and limitations in interpreting trial results.

Main Results:

  • Single-agent ICIs (e.g., cemiplimab) are primarily effective in UV- and radiation-associated angiosarcomas.
  • ICI-TKI combinations (e.g., cabozantinib plus nivolumab) demonstrate significant efficacy in both cutaneous and non-cutaneous angiosarcomas.
  • ICI-chemotherapy combinations show inconsistent results, with some trials indicating potential benefit in specific subsets (e.g., scalp/face angiosarcoma) but lacking overall PFS improvement.

Conclusions:

  • Tyrosine kinase inhibitor-ICI combinations represent a promising strategy for angiosarcoma treatment.
  • Further refinement of chemotherapy-ICI strategies, including optimal sequencing and patient selection, is necessary.
  • Development of robust biomarkers is crucial for identifying patients most likely to benefit from ICI therapy in angiosarcoma.